NUNZ Stock Overview
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nunzia Pharmaceutical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.003 |
| 52 Week High | US$0.65 |
| 52 Week Low | US$0.003 |
| Beta | -2.19 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.91% |
| 5 Year Change | -99.98% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NUNZ | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | -0.2% |
| 1Y | n/a | -23.3% | 25.6% |
Return vs Industry: Insufficient data to determine how NUNZ performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how NUNZ performed against the US Market.
Price Volatility
| NUNZ volatility | |
|---|---|
| NUNZ Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NUNZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NUNZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Sara Gonzales | www.nunziapharma.com |
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com.
Nunzia Pharmaceutical Company Fundamentals Summary
| NUNZ fundamental statistics | |
|---|---|
| Market cap | US$1.30m |
| Earnings (TTM) | -US$96.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NUNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUNZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$96.99m |
| Earnings | -US$96.99m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -95.8% |
How did NUNZ perform over the long term?
See historical performance and comparison